Literature DB >> 7679366

Carcinosarcoma (malignant mixed müllerian (mesodermal) tumor) of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases.

P A de Brito1, S G Silverberg, J M Orenstein.   

Abstract

In an attempt to clarify the histogenesis of carcinosarcoma (malignant mixed müllerian tumor) of the female genital tract, 20 uterine and eight ovarian tumors were studied by light microscopy, transmission electron microscopy, and immunohistochemistry. Cytokeratins (MAK-6 and AE1:AE3) and epithelial membrane antigen were detected in the epithelial component of all tumors and in the stromal component of 15 cases (55%). Vimentin was detected in the stromal component of all cases and was focally positive in the epithelial component of 18 cases (69%). Tumors showing rhabdomyosarcomatous or chondrosarcomatous differentiation were positive for myoglobin and S-100 protein, respectively. At the ultrastructural level epithelial cells were observed in tight clusters (usually surrounded by a basal lamina), in loose aggregates, and singly (sometimes spindle shaped), and were surrounded by cells displaying variable differentiation. The closest examples of "hybrid" epithelial/stromal cells were those with a prominent rough endoplasmic reticulum, cytoplasmic projections, poorly formed intercellular junctions, and an incomplete basal lamina. The observations support the view that carcinosarcomas of the female genital tract could represent examples of biphasic (metaplastic) carcinomas.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679366     DOI: 10.1016/0046-8177(93)90291-n

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  18 in total

1.  Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma.

Authors:  Gloria S Huang; Lydia G Chiu; Juliana S Gebb; Marc J Gunter; Paniti Sukumvanich; Gary L Goldberg; Mark H Einstein
Journal:  Gynecol Oncol       Date:  2007-10-23       Impact factor: 5.482

2.  Carcinosarcoma of the bile duct: a case report and review of literature.

Authors:  Ser Yee Lee; Jinru Shia; T Peter Kingham; William R Jarnagin
Journal:  Hepatobiliary Surg Nutr       Date:  2016-02       Impact factor: 7.293

3.  Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship.

Authors:  Laura Ardighieri; Luigi Mori; Sara Conzadori; Mattia Bugatti; Marcella Falchetti; Carla Maria Donzelli; Antonella Ravaggi; Franco E Odicino; Fabio Facchetti
Journal:  Virchows Arch       Date:  2016-04-08       Impact factor: 4.064

4.  Sarcomatoid carcinomas of the gallbladder: clinicopathologic characteristics.

Authors:  Orhun Cig Taskin; Gizem Akkas; Bahar Memis; Ipek Erbarut Seven; Olca Basturk; Kee-Taek Jang; Juan C Roa; Juan Carlos Araya; Enrique Bellolio; Hector Losada; Juan Sarmiento; Serdar Balci; Burcin Pehlivanoglu; Michelle D Reid; Jill Koshiol; Volkan Adsay
Journal:  Virchows Arch       Date:  2019-06-08       Impact factor: 4.064

Review 5.  Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?

Authors:  W G McCluggage
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

Review 6.  How to approach the many faces of endometrioid carcinoma.

Authors:  Anais Malpica
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

7.  Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma.

Authors:  Gloria S Huang; Rebecca C Arend; Maomi Li; Marc J Gunter; Lydia G Chiu; Susan Band Horwitz; Gary L Goldberg
Journal:  Am J Obstet Gynecol       Date:  2009-02-06       Impact factor: 8.661

8.  Malignant mixed Mullerian tumors of the uterus: histopathological evaluation of cell cycle and apoptotic regulatory proteins.

Authors:  Rani Kanthan; Jenna-Lynn B Senger; Dana Diudea
Journal:  World J Surg Oncol       Date:  2010-07-19       Impact factor: 2.754

9.  Establishment and characterization of the NEYS cell line derived from carcinosarcoma of human ovary with special reference to the susceptibility test of anticancer drugs.

Authors:  Yoshiaki Ide; Taka Nakahara; Masanori Nasu; Noriko Tominaga; Akihiro Ohyama; Toshiaki Tachibana; Makoto Yasuda
Journal:  Hum Cell       Date:  2009-06-23       Impact factor: 4.174

10.  A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.

Authors:  Susana M Campos; William E Brady; Katherine M Moxley; Roisin E O'Cearbhaill; Paula S Lee; Paul A DiSilvestro; Jacob Rotmensch; Peter G Rose; Premal H Thaker; David M O'Malley; Parviz Hanjani; Rosemary E Zuna; Martee L Hensley
Journal:  Gynecol Oncol       Date:  2014-03-01       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.